Ciclesonide
Ciclesonide is a pharmaceutical drug with 47 clinical trials. Historical success rate of 97.8%.
Success Metrics
Based on 45 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
42
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
97.8%
45 of 46 finished
2.2%
1 ended early
0
trials recruiting
47
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Inhaled Ciclesonide for Outpatients With COVID19
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
Clinical Trials (47)
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Inhaled Ciclesonide for Outpatients With COVID19
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
The Mannitol-Asthma-Ciclesonide-Study
Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)
Effect of High Dose Ciclesonide on Asthma Control
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)
Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 47